Molecular pathology of breast cancer the journey from traditional practice toward embracing the complexity of a molecular classification

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 5, 2011, Pages 544-557

  Gruver, Aaron M ^a   Portier, Bryce P ^a   Tubbs, Raymond R ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADENOCARCINOMA; ARTICLE; BREAST TUMOR; CLASSIFICATION; FEMALE; GENETICS; HUMAN; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PROGNOSIS;

ADENOCARCINOMA; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS;

EID: 79956372637     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (134)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [published online ahead of print June 17, 2010]. Int J Cancer. doi:10.1002/ijc.25516.
2. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33(5):315-318.
3. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
4. Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas. 2010;65(4):308-314.
5. Eniu A, Carlson RW, Aziz Z, et al. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J. 2006;12(suppl 1):S38-S53. (Pubitemid 43385272)
6. Shyyan R, Masood S, Badwe RA, et al. Breast cancer in limited-resource countries: diagnosis and pathology. Breast J. 2006;12(suppl 1):S27-S37.
7. Tubbs RR, Stoler MH. Cell and Tissue Based Molecular Pathology: A Volume in the Series Foundations in Diagnostic Pathology. 1st ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2009.
8. Haspel RL, Arnaout R, Briere L, et al. A call to action: training pathology residents in genomics and personalized medicine. Am J Clin Pathol. 2010;133(6): 832-834.
9. Walk EE. The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med. 2009;133(4):605-610.
10. Sistrunk WE, Maccarty WC. Life expectancy following radical amputation for carcinoma of the breast: a clinical and pathologic study of 218 cases. Ann Surg. 1922;75(1):61-69.
11. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718-730.
12. Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. World Health Organization Classification of Tumours; vol 5.
13. Stenkvist B, Bengtsson E, Eriksson O, Jarkrans T, Nordin B, WestmanNaeser S. Histopathological systems of breast cancer classification: reproducibility and clinical significance. J Clin Pathol. 1983;36(4):392-398. (Pubitemid 13163391)
14. Schiodt T. Breast carcinoma: a histological and prognostic study of 650 followed-up cases. Dan Med Bull. 1967;14(9):239-243.
15. Rosen PP. Rosen's Breast Pathology. Philadelphia, PA: Lippincott-Raven Publishers; 1997.
16. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975,36(1):1-85.
17. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23(suppl 2):S60-S64.
18. Beatson G. On the treatment of inoperable cases of carcinoma of the mammary: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2(3802):104-107.
19. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26(1):1-10.
20. Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010;16(7):799-803.
21. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, et al. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 1975;35(11, pt 1):3187-3194.
22. Pichon MF, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980; 40(91:3357-3360.
23. Pichon MF, Pallud C, Hacene K, Milgrom E. Prognostic value of progesterone receptor after long-term follow-up in primary breast cancer. Fury Cancer. 1992;28A(10):1676-1680.
24. Nomura Y, Miura S, Koyama H, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer: a univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the study group for the Japanese breast cancer society on hormone receptors and prognosis in breast cancer. Cancer. 1992;69(1):153-164.
25. Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M. The value of estrogen and progesterone receptor determinations in advanced breast cancer: estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer. 1991;68(4):867-872.
26. Howell A, Barnes DM, Harland RN, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984;1(8377):588-591. (Pubitemid 14156512)
27. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229(4717):974-976. (Pubitemid 16248488)
28. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986;1(8484):765-767.
29. Zhou D, Battifora H, Yokota J, Yamamoto T, Cline MJ. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res. 1987;47(22):6123-6125. (Pubitemid 18018764)
30. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63(3):447-450.
31. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45): 6469-6487. (Pubitemid 47530601)
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. (Pubitemid 17231334)
33. Drebin JA, Link VC, Greene Ml. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded pi 85 molecule exert synergistic anti-tumor effects in vivo. Oncogene. 1988;2(3):273-277. (Pubitemid 18085307)
34. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol. 2007;38(8):1105-1122. (Pubitemid 47058171)
35. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21 (suppl 2):S8-S15. (Pubitemid 351592775)
36. Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol. 2010;63(3):210-219.
37. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43. (Pubitemid 46174133)
38. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-e72.
39. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-368.
40. Gall JG, Pardue ML. Formation and detection of RNA-DNA hybrid molecules in etiological preparations. Proc Natl Acad Sci USA. 1969;63(2): 378-383.
41. Pardue ML, Gall JG. Molecular hybridization of radioactive DNA to the DNA of cytological preparations. Proc Natl Acad Sci U S A. 1969;64(2):600-604.
42. Trask BJ. Human cytogenetics: 46 chromosomes, 46 years and counting. Nat Rev Genet. 2002;3(10):769-778.
43. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157(5):1467-1472.
44. Tubbs R, Pettay J, Hicks D, et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol. 2004;35(6):589-594. (Pubitemid 41404644)
45. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol. 2008;3:41.
46. Downs-Kelly E, Pettay J, Hicks D, et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation brightfield metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 2005; 29(11):1505-1511. (Pubitemid 41513301)
47. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol. 2010;34(6):767-776.
48. Powell RD, Pettay JD, Powell WC, et al. Metallographic in situ hybridization. Hum Pathol. 2007;38(8):1145-1159. (Pubitemid 47058176)
49. Kurosumi M. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Breast Cancer. 2009;16(4):284-287.
50. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
51. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-8423. (Pubitemid 36842560)
52. van't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003;5(1):57-58. (Pubitemid 36553581)
53. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profi les. Proc Natl Acad Sci USA. 2001;98(20):11462-11467. (Pubitemid 32928751)
54. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large wellcharacterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116(3):340-350. (Pubitemid 40993329)
55. Da Silva L, Clarke C, Lakhani SR. Demystifying basal-like breast carcinomas. J Clin Pathol. 2007;60(12):1328-1332. (Pubitemid 350247248)
56. Constantinidou A, Jones RL, Reis-Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010;10(8): 1197-1213.
57. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010; 17(3): 173-176.
58. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009;41(1):40-47.
59. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. 2007;14(5):358-373. (Pubitemid 47312292)
60. Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat. 2009;113(3):411-422.
61. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59(7):729-735. (Pubitemid 44048783)
62. Rakha E, Reis-Filho JS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med. 2009,-133(6):860-868.
63. Luck AA, Evans AJ, James JJ, et al. Breast carcinoma with basal phenotype: mammographie findings. AJR Am Roentgenol. 2008;191(2):346-351.
64. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007;14(6):419-430. (Pubitemid 350307665)
65. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139. (Pubitemid 351538762)
66. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basallike subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271. (Pubitemid 43117611)
67. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-1485. (Pubitemid 37279334)
68. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26(14):2126-2132. (Pubitemid 46514749)
69. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-5853. (Pubitemid 44453440)
70. Rakha EA, Reis-Filho JS, Ellis IO. Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology. 2008;75(2):95-103. (Pubitemid 351820727)
71. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216(2):141-150.
72. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344(8):539-548. (Pubitemid 32167867)
73. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871) :530-536. (Pubitemid 34130608)
74. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sei U S A. 2001; 98(19): 10869-10874. (Pubitemid 32878711)
75. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. (Pubitemid 35461656)
76. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-1691.
77. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-3277.
78. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expressionbased predictors for breast cancer. N Engl J Med. 2006;355(6):560-569. (Pubitemid 44200649)
79. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23(29):7350-7360. (Pubitemid 46202348)
80. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
81. Sotiriou C, Desmedt C. Gene expression profiling in breast cancer. Ann Oncol. 2006;17(suppl 10):x259-x262. (Pubitemid 44542019)
82. Sorlie T, Perou CM, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5(11):2914-2918. (Pubitemid 44849019)
83. Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology. 2008;52(1):67-81. (Pubitemid 350265184)
84. Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol. 2009;16(4):204-215.
85. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477-493. (Pubitemid 351872866)
86. Kim C, Taniyama Y, Paik S. Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. Arch Pathol Lab Med. 2009;133(6):855-859.
87. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26(5):721-728. (Pubitemid 351264384)
88. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26(5):729-735. (Pubitemid 351264385)
89. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict oncotype DX recurrence score. Mod Pathol. 2008; 21(10):1255-1261.
90. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol. 2009;18(3):125-132.
91. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev. 1996;76(1):69-125. (Pubitemid 26048279)
92. Taylor-Papadimitriou J, Stampfer M, Bartek J, et al. Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Sci. 1989;94(pt 3): 403-413. (Pubitemid 20002838)
93. Subik K, Lee JF, Baxter L, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 2010;4:35-41.
94. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258(5083):818-821.
95. Kallioniemi OP, Kallioniemi A, Sudar D, et al. Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol. 1993;4(1):41-46.
96. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20(2):207-211. (Pubitemid 28455458)
97. Carvalho B, Ouwerkerk E, Meijer GA, Ylstra B. High resolution microarray comparative genomic hybridisation analysis using spotted oligonucleotides. J Clin Pathol. 2004;57(6):644-646. (Pubitemid 38725769)
98. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res. 2006;8(3):210.
99. Callagy G, Jackson L, Caldas C. Comparative genomic hybridization using DNA from laser capture microdissected tissue. Methods Mol Biol. 2005;293:39-55.
100. Weiss MM, Hermsen MA, Meijer GA, et al. Comparative genomic hybridisation. Mol Pathol. 1999;52(5):243-251.
101. Johnson NA, Hamoudi RA, lchimura K, et al. Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest. 2006;86(9):968-978. (Pubitemid 44268171)
102. Hostetter G, Kim SY, Savage S, et al. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. Nucleic Acids Res. 2010;38(2):e9.
103. Gunn SR, Robetorye RS, Mohammed MS. Comparative genomic hybridization arrays in clinical pathology: progress and challenges. Mol Diagn Ther. 2007; 11 (2):73-77. (Pubitemid 46572567)
104. Gunn S, Gorre M, Mohammed M, et al. Validation of an array CGH test for HER2 status using tumor-targeted DNA extraction from formalin fixed tissue: comparison with fresh frozen tissue results. Cancer Res. 2009;6924(suppl). Abstract 6038.
105. Alvarez K, Kash SF, Lyons-Weiler MA, et al. Reproducibility and performance of virtual karyotyping with SNP microarrays for the detection of chromosomal imbalances in formalin-fixed paraffin-embedded tissues. Diagn Mol Pathol. 2010;19(3):127-134.
106. Baak-Pablo R, Dezentje V, Guchelaar HJ, van der Straaten T. Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn. 2010;12(6):746-749.
107. Gunn S, Yeh IT, Lytvak I, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer. 2010; 10:396.
108. Grimm EE, Schmidt RA, Swanson PE, Dintzis SM, Allison KH. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol. 2010;134(2):284-292.
109. Rapaport F, Leslie C. Determining frequent patterns of copy number alterations in cancer. PLoS One. 2010;5(8):e12028.
110. Shaffer LG, Beaudet AL, Brothman AR, et al. Microarray analysis for constitutional cytogenetic abnormalities. Genet Med. 2007;9(9):654-662. (Pubitemid 47415276)
111. Schubert F, Tausch B, Jóos S, Eils R. CGH-profiler: data mining based on genomic aberration profiles. BMC Bioinformatics. 2005;6:188.
112. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 2007; 4(10):828-833. (Pubitemid 350055580)
113. Franck J, Arafah K, Elayed M, et al. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol Cell Proteomics. 2009;8(9): 2023-2033.
114. Lemaire R, Menguellet SA, Stauber J, et al. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the IIS proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J. Proteome Res. 2007;6(11):4127-4134.
115. Chaurand P, Schwartz SA, Caprioli RM. Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr Opin Chem Biol. 2002;6(5):676-681. (Pubitemid 35284200)
116. Fournier I, Day R, Salzet M. Direct analysis of neuropeptides by in situ MALDI-TOF mass spectrometry in the rat brain. Neuro Endocrinol Lett. 2003; 24(1-2):9-14. (Pubitemid 36559493)
117. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001;7(4):493-496. (Pubitemid 32298555)
118. Rauser S, Marquardt C, Balluff B, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res. 2010;9(4):1854-1863.
119. Schwartz SA, Weil RJ, Thompson RC, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 2005;65(17):7674-7681. (Pubitemid 41297241)
120. Bahr U, Stahl-Zeng J, Gleitsmann E, Karas M. Delayed extraction time-of-flight MALDI mass spectrometry of proteins above 25,000 Da. J Mass Spectrom. 1997;32(10):1111-1116. (Pubitemid 27454256)
121. Westmacott G, Frank M, Labov SE, Benner WH. Using a superconducting tunnel junction detector to measure the secondary electron emission efficiency for a microchannel plate detector bombarded by large molecular ions. Rapid Commun Mass Spectrom. 2000;14(19):1854-1861.
122. Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol. 2010;4(3):242-254.
123. Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19(3):165-171.
124. Morrow PK, Hortobagyi GN. Management of breast cancer in the genome era. Annu Rev Med. 2009;60:153-165.
125. Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest. 2007;25(8):659-665. (Pubitemid 350223167)
126. Holm K, Hegardt C, Staaf J, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010;12(3):R36.
127. Flanagan JM, Cocciardi S, Waddell N, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet. 2010;86(3):420-433.
128. de Ronde J, Wessels L, Wesseling J. Molecular subtyping of breast cancer: ready to use? Lancet Oncol. 2010; 11(4):306-307.
129. Baltogiannis G, Katsios C, Zografos GC, Roukos DH. HER-2-negative breast cancer limitations and next-generation sequencing technology promises. Ann Surg Oncol. 2010; 17(6): 1720.
130. Ray PS, Wang J, Qu Y, et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010;70(10): 3870-3876.
131. Hicks DG, Janarthanan BR, Vardarajan R, et al. The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer. 2010;10:108.
132. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-10874. (Pubitemid 32878711)
133. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
134. Hardiman G. Microarray Innovations: Technology and Experimentation. Vol 11. Boca Raton, FL: CRC Press; 2009.